HIGHLIGHTS
- who: Nawale Hajjaji from the Breast Department, Oscar Lambret Center, Lille, France, Prism Laboratory, Inserm, University of Lille, Lille have published the Article: Should a Multigene Signature be Used in all Luminal Early Breast Cancers, in the Journal: (JOURNAL)
- what: The study aims were to analyze in a homogeneous real life cohort (i) which clinical risk groups triggered the use of the PAM50-based Prosigna R assay, and_(ii) their concordance with the genomic risk. Two cohorts of patients tested with Prosigna R were available and pooled totalizing 222 cases: a cohort of 159 breast . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.